Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease

Background To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease. Objective To determine whether plasma levels of amyloid β protein (Aβ40 and Aβ42) are useful for identifying cognitively normal elderly white subjects at increased risk for mild cognitive impairment (MCI) and AD. Design Using well-established sandwich enzyme-linked immunosorbent assays, plasma Aβ40 and Aβ42 levels were analyzed at baseline in a prospective, elderly white cohort followed up for 2 to 12 (median, 3.7) years to detect incident cases of MCI or AD. Setting Cognitively normal, community-based white volunteers recruited from primary care settings into the Mayo Rochester Alzheimer Disease Patient Registry. Patients We followed up 563 cognitively normal white volunteers (median age, 78 years; 62% female) who had at least 1 follow-up visit after measurement of baseline plasma Aβ levels. Main Outcome Measures The primary outcome was time to development of MCI or AD. The secondary outcome was the annualized rate of cognitive change in patients for whom we had 2 Mattis Dementia Rating Scale evaluations 3 to 7 years apart. Results During follow-up, 53 subjects developed MCI or AD. Subjects with plasma Aβ42/Aβ40 ratios in the lower quartiles showed significantly greater risk of MCI or AD ( P  = .04, adjusted for age and apolipoprotein E genotype). Comparison of subjects with plasma Aβ42/Aβ40 ratios in the lowest vs the highest quartile gave a relative risk of 3.1 (95% confidence interval, 1.1-8.3). After adjusting for age and apolipoprotein E genotype, regression analysis using annualized changes in the Dementia Rating Scale scores as an outcome variable showed that participants with lower Aβ42/Aβ40 ratios had greater cognitive decline ( P  = .02). Conclusion The plasma Aβ42/Aβ40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD.

[1]  A. Hofman,et al.  Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.

[2]  P. Whitehouse,et al.  Mild cognitive impairment , 2006, Lancet.

[3]  G. Kemmler,et al.  Plasma amyloid β protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy , 2005, Neurobiology of Aging.

[4]  P. Fischer,et al.  Plasma amyloid beta protein 42 in non-demented persons aged 75-years: Effects of concomitant medication and medial temporal lobe atrophy , 2005, Alzheimer's & Dementia.

[5]  I. Alafuzoff,et al.  α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia , 2005, Annals of neurology.

[6]  Tore Wentzel-Larsen,et al.  The rate of cognitive decline in Parkinson disease. , 2004, Archives of neurology.

[7]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[8]  P. Hobson,et al.  Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom , 2004, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. T. Greenamyre,et al.  Parkinson's--Divergent Causes, Convergent Mechanisms , 2004, Science.

[10]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[11]  R. Mayeux,et al.  Plasma A&bgr;40 and A&bgr;42 and Alzheimer’s disease: Relation to age, mortality, and risk , 2003 .

[12]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[13]  J. Growdon,et al.  Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels , 2003 .

[14]  H. Soininen,et al.  Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. , 2003, Journal of neuropathology and experimental neurology.

[15]  H. Soininen,et al.  Regional Distribution of α‐Synuclein Pathology in Unimpaired Aging and Alzheimer Disease , 2003 .

[16]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[17]  Yaakov Stern,et al.  Combined effect of age and severity on the risk of dementia in Parkinson's disease , 2002, Annals of neurology.

[18]  Udo Rüb,et al.  Where Does Parkinson Disease Pathology Begin in the Brain? , 2002, Journal of neuropathology and experimental neurology.

[19]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[20]  D. Schaid,et al.  Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees , 2001 .

[21]  B. Tycko,et al.  Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome , 2001, Neuroscience Letters.

[22]  K. Blennow,et al.  Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. , 2001, Archives of neurology.

[23]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[24]  P. Pahapill,et al.  The pedunculopontine nucleus and Parkinson's disease. , 2000, Brain : a journal of neurology.

[25]  G. Stebbins,et al.  Differential progression of motor impairment in levodopa‐treated Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.

[26]  H. Wiśniewski,et al.  Plasma amyloid β‐peptide 1–42 and incipient Alzheimer's disease , 1999 .

[27]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[28]  B. Thies,et al.  Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease. , 1999 .

[29]  A. Kishore,et al.  Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. , 1998, Parkinsonism & related disorders.

[30]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[31]  M. Yamada,et al.  [Dementia rating scale]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[32]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[33]  S. Younkin,et al.  Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). , 1995, The Journal of biological chemistry.

[34]  H. Petit,et al.  Which factors predict cognitive decline in Parkinson's disease? , 1995, Journal of neurology, neurosurgery, and psychiatry.

[35]  M Schulzer,et al.  Clinical observations on the rate of progression of idiopathic parkinsonism. , 1994, Brain : a journal of neurology.

[36]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[37]  E. Tangalos,et al.  The short test of mental status. Correlations with standardized psychometric testing. , 1991, Archives of neurology.

[38]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[39]  Y. Agid,et al.  Striatal dopamine deficiency in parkinson's disease: Role of aging , 1989, Annals of neurology.

[40]  S Greenland,et al.  Concepts of interaction. , 1980, American journal of epidemiology.

[41]  N. Lassen,et al.  Multi-infarct dementia. A cause of mental deterioration in the elderly. , 1974, Lancet.

[42]  K. Jellinger α-Synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study , 2003, Acta Neuropathologica.

[43]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[44]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[45]  Y Agid,et al.  Biochemistry of Parkinson's disease 28 years later: A critical review , 1989, Movement disorders : official journal of the Movement Disorder Society.

[46]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[47]  A. Rey Lexamen psychologique : Dans les cas d'encephalopathie traumatique (Les problemes) , 1941 .

[48]  A. Rey L'examen psychologique dans les cas d'encéphalopathie traumatique. (Les problems.). , 1941 .